Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: easy alliances rather than big deals the focus at JP Morgan; multiple company roundups from JPM; and Lilly braces for impact of US CMS decision on Aduhelm.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 14 January 2022, including: easy alliances rather than big deals the focus at J.P. Morgan; other roundups from the JPM meeting; and Eli Lilly and Company braces for impact of CMS decision on Aduhelm.
This and all our other podcasts are available on the Informa Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "J.P. Morgan Day 1: Pharma Execs Offer Big Talk Instead Of Big Deals" - Scrip, 10 Jan, 2022.)
(Also see "J.P. Morgan Day 2: What's Next For Pharma, From Alzheimer's To Omicron" - Scrip, 11 Jan, 2022.)
(Also see "Lilly Braces For Impact Of CMS Draft Coverage Decision On Biogen’s Aduhelm" - Scrip, 11 Jan, 2022.)